Miguel Abboud to Hemoglobin, Sickle
This is a "connection" page, showing publications Miguel Abboud has written about Hemoglobin, Sickle.
Connection Strength
1.258
-
Voxelotor for the treatment of sickle cell disease in pediatric patients. Expert Rev Hematol. 2022 06; 15(6):485-492.
Score: 0.818
-
Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11?years. Pediatr Blood Cancer. 2022 08; 69(8):e29716.
Score: 0.203
-
A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. N Engl J Med. 2019 08 08; 381(6):509-519.
Score: 0.166
-
Effect of chronic transfusion therapy on progression of neurovascular pathology in pediatric patients with sickle cell anemia. Blood Cells Mol Dis. 2011 Aug 15; 47(2):125-8.
Score: 0.024
-
Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001 Dec; 139(6):785-9.
Score: 0.012
-
Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography. N Engl J Med. 1998 Jul 02; 339(1):5-11.
Score: 0.010
-
Stroke prevention trial in sickle cell anemia. Control Clin Trials. 1998 Feb; 19(1):110-29.
Score: 0.009
-
A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. The Preoperative Transfusion in Sickle Cell Disease Study Group. N Engl J Med. 1995 Jul 27; 333(4):206-13.
Score: 0.008
-
Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 1995 Jun; 126(6):896-9.
Score: 0.008